The global market for continuous glucose monitoring (CGM) technology has reached a critical inflection point as the industry’s two primary titans, Abbott and Dexcom, report diverging financial trajectories ahead of a transformative regulatory shift. As of November 2026, the medical technology sector is closely monitoring the Centers for Medicare and Medicaid Services (CMS), which is widely expected to finalize a landmark decision regarding coverage for Type 2 diabetes patients who do not require insulin. This anticipated expansion represents one of the largest potential increases in the addressable market for glucose sensors in a decade, yet the path toward this milestone has revealed stark differences in how the two market leaders are weathering current economic headwinds.
While both companies stand to gain significantly from the inclusion of millions of non-insulin-using Type 2 patients into the reimbursement fold, Abbott has signaled a period of cooling growth and intensified pricing competition. Conversely, Dexcom has maintained a more optimistic posture, reporting stable pricing and robust market share gains despite the looming loss of a major pharmacy benefit manager (PBM) contract. The contrast highlights a maturing market where clinical evidence, payer relationships, and international pricing strategies are becoming the primary levers of corporate success.
The CMS Expansion: A New Frontier for Type 2 Diabetes Management
The focal point for both Abbott and Dexcom remains the imminent decision by the CMS to broaden coverage for CGMs. Historically, reimbursement for these devices was largely restricted to patients with Type 1 diabetes or those with Type 2 who required intensive insulin therapy. However, a growing body of clinical evidence suggests that the real-time feedback provided by CGMs can significantly improve glycemic control and lifestyle choices for the broader population of Type 2 patients, even those managed through oral medications or diet alone.
Dexcom Chief Operating Officer Jake Leach confirmed during a November 2026 earnings call that the company expects a formal CMS announcement before the end of the calendar year. This optimism is rooted in the results of a high-profile study published in the New England Journal of Medicine (NEJM) last month. The study demonstrated that Type 2 patients not on insulin experienced a statistically significant reduction in HbA1c levels when using CGMs compared to the traditional standard of care, which relies on intermittent finger-stick testing.
Leach noted that Dexcom has been proactive in sharing these findings with medical directors across the country. The company’s strategy is not merely to secure Medicare coverage but to ensure that the American Diabetes Association (ADA) integrates CGM use into its upcoming "Standards of Care" for all Type 2 patients. Such a move would effectively codify the device as a baseline necessity rather than a premium accessory, potentially triggering a massive wave of private insurance adoption following the Medicare lead.
Abbott’s Growth Slowdown and International Headwinds
Despite its long-standing dominance in the CGM space with the FreeStyle Libre line, Abbott reported a noticeable deceleration in its diabetes division during the third quarter of 2026. CEO Robert Ford attributed this slowdown to a combination of factors, primarily the "reimbursement gap" for non-insulin users and mounting pricing pressures in overseas markets.
Abbott’s decision to revise its annual sales growth forecast downward reflects a cooling in its diabetes and electrophysiology segments. Ford explained that the company has reached a temporary ceiling in the U.S. market, where the easiest-to-reach patient populations have already been captured. Without the CMS expansion, reaching the remaining millions of Type 2 patients has proven difficult and costly. "It’s been harder to reach people with Type 2 diabetes without a reimbursement expansion," Ford told investors, though he maintained that the company is poised for "strong reimbursement growth" once the federal policy changes take effect.
Perhaps more concerning for Abbott is the situation in international markets. As a company that traditionally holds the majority market share in many European and Asian territories, Abbott has become a target for aggressive pricing from newer, low-cost competitors. To defend its market position, Abbott has been forced to implement pricing adjustments—a move that impacts profit margins even as it preserves volume. This defensive posture suggests that the era of uncontested dominance for the FreeStyle Libre may be giving way to a more fragmented and price-sensitive global landscape.
Dexcom’s Resilience and Strategic Market Positioning
In contrast to Abbott’s cautious outlook, Dexcom appears to be navigating the current environment with greater price stability. CFO Jereme Sylvain reported that the company has not seen the same "pricing degradation" affecting its chief rival. Sylvain emphasized that Dexcom’s products are "priced right" for their clinical value proposition, allowing the company to continue taking market share from competitors.
While Dexcom does not have the same level of international exposure as Abbott—meaning it is less affected by the specific regional price wars Ford described—it has focused on a premium-tier strategy that emphasizes integration with automated insulin delivery (AID) systems. This focus on the high-end Type 1 and intensive Type 2 markets has provided a buffer against the pricing volatility seen in the broader consumer-facing segments.
However, Dexcom is not without its own challenges. The company is preparing for a significant shift in its domestic payer landscape. Starting in 2027, certain formulary designs under CVS Caremark and Aetna Commercial will switch from exclusive coverage of Dexcom sensors to exclusive coverage of Abbott’s products. While this would typically be a cause for alarm, Dexcom executives have sought to downplay the impact. Sylvain noted that the PBM accounts in question represent less than 4% of Dexcom’s total revenue. Furthermore, CEO Jake Leach pointed out that patients who lose coverage through a pharmacy benefit may still be able to access Dexcom products through their durable medical equipment (DME) benefit, a different administrative channel that often provides more flexibility for specialized medical tech.
The 2027 Formulary Shift: A Payer Tug-of-War
The upcoming "flip" in the CVS Caremark and Aetna formulary is a microcosm of the larger battle for payer dominance. Abbott’s CEO Robert Ford characterized the win as a "pretty significant" victory that will bolster the company’s 2027 performance. By securing exclusive or preferred status with one of the nation’s largest PBMs, Abbott is leveraging its scale to offer pricing structures that are difficult for smaller or more specialized firms to match.
The shift underscores a growing trend in the medtech industry where "preferred" status is determined as much by financial rebates and volume discounts as by clinical outcomes. Dexcom’s Leach expressed a preference for "equal access" models, where multiple competitors are available to patients. He argued that the products are not always interchangeable, particularly for pediatric patients with Type 1 diabetes who rely on specific sensor-pump integrations. If a child’s insulin pump is only compatible with a Dexcom sensor, but their insurance switches to Abbott-exclusive coverage, it creates a clinical hurdle that can complicate disease management.
Chronology of the CGM Market Evolution (2024–2026)
To understand the current state of the Abbott-Dexcom rivalry, it is necessary to look at the timeline of events leading up to the present:
- Mid-2024: Both companies launch next-generation sensors (Libre 3 and G7) with smaller footprints and faster warm-up times, intensifying the race for user-friendliness.
- Early 2025: Initial pilot programs for non-insulin Type 2 patients show promising results, leading to increased lobbying efforts for Medicare expansion.
- June 2026: Dexcom shares definitive study results at the American Diabetes Association’s Scientific Sessions, proving the efficacy of CGMs for the non-insulin population.
- October 2026: The New England Journal of Medicine publishes the landmark study, providing the "gold standard" evidence required for federal policy changes.
- November 2026: Abbott cuts its growth forecast, citing international pricing pressure, while Dexcom maintains its guidance despite the loss of the CVS Caremark contract.
- Late 2026 (Expected): CMS is anticipated to issue its final National Coverage Determination (NCD), opening the door for millions of new users.
Analysis of Implications: The Future of Metabolic Health
The divergence between Abbott and Dexcom suggests that the CGM market is bifurcating into two distinct strategies. Abbott appears to be pursuing a "mass market" approach, utilizing its massive manufacturing scale and PBM partnerships to become the default choice for the millions of Type 2 patients expected to enter the market. This strategy requires lower price points and high-volume turnover, making the company more susceptible to international competition and the need for aggressive "payer flips."
Dexcom, meanwhile, is doubling down on its "clinical specialist" identity. By focusing on the most complex patients and maintaining high levels of integration with other medical devices, Dexcom is betting that a significant portion of the market will remain loyal to its brand regardless of PBM shifts. Their reliance on the DME channel and clinical evidence published in prestigious journals like the NEJM suggests a long-term play for the "quality-first" segment of the population.
The broader implication for the healthcare system is overwhelmingly positive. As these two giants compete, the cost of CGM technology is likely to continue its downward trend, making life-saving data more accessible to the global population. The transition of CGM from a niche tool for Type 1 patients to a foundational pillar of metabolic health for Type 2 patients represents a shift toward preventative, data-driven medicine.
As the industry awaits the final word from CMS, the stakes could not be higher. For Abbott, the expansion is a necessary catalyst to reverse its recent slowdown. For Dexcom, it is an opportunity to prove that its clinical-first strategy can win over the mass market. Regardless of which company captures more "share of arm," the ultimate winners will be the patients who, for the first time, will have the tools to manage their diabetes with unprecedented precision and federal financial support.
